Explore contributions, investments and results in our fight against AIDS, tuberculosis and malaria around the world.
15 July 2019
The Quality Assurance Information Notice 2016-02 providing recommendations regarding the procurement and the distribution of finished pharmaceutical products using active pharmaceutical ingredients manufactured at IPCA Ratlam Manufacturing Site is withdrawn. This is to reflect the Sourcing and Supply Chain Department decision that no specific quality assurance requirements are currently implemented by Global Fund quality assurance on IPCA finished pharmaceuticals products.
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.